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Hemangiomas, the most common vascular tumors 
in Caucasian infants, occur in approximately 1% of 
normal neonates [1] and 12% of normal year-old child-
ren [2]; the incidence increases to 20% in premature 
infants weighing less than 1000 g [3]. In a recent study, 
Dr Drolet et al. [4] reported an increased rate of he-
mangiomas (an increase of 40% in the last 20 years) in 
the United States and found the increase to be linked 
to the rise in the frequency of low birth weight infants. 
These lesions are characterized by rapid proliferation 
of capillaries during the first year of life (proliferative 
stage), followed by a slowed growth and regression of 
the tumor over the next 5–6 years (involuting stage), 
with complete regression of the lesion in 90% of af-
fected individuals by the age of 10–12 years [1, 5]. 
Though the majority have minor vascular birthmarks 
that resolve without treatment, 10% of hemangiomas 
cause severe skin distortion or problems with vision 
or brea thing [6]. Such hemangiomas are generally 
treated with agents, such as systemic corticosteroid, 
vincristine, and interferon-alpha, which are associ-
ated with toxic effects. In addition, when these tumors 
obstruct the airway or deform the cornea, surgical 
removal becomes necessary.
Although the pathomechanism of hemangioma 
is unknown, the rapid proliferation of endothelial 
cells suggests the importance of angiogenesis. He-
mangiomas originate from a single endothelial cell 
precursor and tumors are composed of microves-
sels lined by mitotically active endothelial cells and 
pericytes [7]. Proliferating hemangiomas are highly 
angiogenic with urinary basic fibroblast growth factor 
levels 25–50 times the level seen in normal controls 
[6]. In studying the cellular markers during the phases 
of hemangioma, Takahashi et al. [6] found that the 
proliferating phase was defined by high expression of 
type IV collagenases and vascular endothelial growth 
factor (VEGF) and the involuting phase — by elevated 
expression of tissue inhibitor of metalloproteinases 
(TIMP)1. High expression of bFGF and urokinases were 
seen in both the proliferating and involuting phases. 
These results may be used to evaluate therapeutic 
agents [6].
Consumption of a plant-based diet has been as-
sociated with prevention of the development and 
progression of cancer [8, 9]. Antiangiogenic proper-
ties of edible plant products, such as flavonoids, have 
been reported [10, 11]. In previous studies we found 
that a NM containing lysine, proline, arginine, ascorbic 
acid, and green tea extract demonstrated significant 
antiangiogenic activity utilizing the chorioallantoic 
membrane (CAM) assay in chick embryos and bFGF-
induced vessel growth in C57BL/6J female mice in the 
mouse Matrigel plug assay [12]. Furthermore, in vitro 
we observed that NM decreased osteosarcoma U2OS 
cell expression of VEGF, angiopoietin-2, bFGF, PDGF 
and TGF beta-1 [12]. In a study on human umbilical 
vein endothelial cells (HUVEC), we found NM inhibited 
HUVEC migration, MMP expression, Matrigel invasion 
and capillary tube formation [13].
In this study we investigated the effect of an 
NM-supplemented diet on tumor growth of murine 
hemangioendothelioma (EOMA) cells administered 
subcutaneously in male athymic mice. We chose 
a mouse EOMA model as this model has been utilized 
to test the efficacy of antiangiogenic medications in 
inhibiting vascular tumor proliferation [14]. Further, 
we tested the effect of NM on EOMA cells in vitro, 
inclu ding cell proliferation, MMP secretion, Matrigel 
invasion and apoptosis.
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MATERIALS AND METHODS
In vivo studies. Male athymic mice (NCr-nu/nu), 
approximately five weeks of age on arrival, were pur-
chased from Simonsen Laboratories, Gilroy, CA and 
maintained in microisolator cages under pathogen-
free conditions on a 12-h light/12-h dark schedule for 
a week. All procedures were performed according to 
humane and customary care and use of experimental 
animals and followed a protocol approved by internal 
institutional animal safety review committee.
After housing for a week, the mice (n = 12) were 
inoculated subcutaneously with 3x106 EOMA cells 
(ATCC) in 0.2 ml PBS and 0.1 ml Matrigel (BD Biosci-
ence, Bedford, MA). After injection, the mice were ran-
domly divided into two groups; group A mice were fed 
regular Purina mouse chow and group B — the regular 
diet supplemented with 0.5% NM (w/w). During the 
study, the mice consumed, on the average, 4 g of their 
respective diets per day. Thus, the supplemented mice 
received approximately 20 mg of NM per day. After four 
weeks, the mice were sacrificed and their tumors were 
excised and processed for histology. Mean weight of 
mice at initiation of study and termination of study did 
not differ significantly between the groups.
Tissue samples were fixed in 10% buffered forma-
lin. All tissues were embedded in paraffin and cut at 
4–5 microns. Sections were deparaffinized through 
xylene and graduated alcohol series to water and 
stained with hematoxylin and eosin (H & E) for evalu-
ation using a standard light microscope.
Cell line and culture. EOMA cell line was obtained 
from ATCC (American Type Culture Collection, Rockville, 
MD). EOMA cells were maintained in DME (Dulbecco’s 
modified Eagle’s) medium supplemented with 10% fetal 
bovine serum, 100 U/ml penicillin and 100 μg/ml strep-
tomycin in 24-well tissue culture plates (Costar, Cam-
bridge, MA). The media and sera used were obtained 
from ATCC, and antibiotics (penicillin and streptomycin) 
were from Gibco BRL, Long Island, NY.
At near confluence, the cells were treated with the 
NM, dissolved in media and tested at 0, 10, 50, 100, 
500, and 1000 μg/ml in triplicate at each dose. Phorbol 
12-myristate 13-acetate (PMA), 200 ng/ml was added 
to cells to induce MMP-9 secretion. The plates were 
then returned to the incubator.
Composition of the  NM. The NM was composed 
of the following in the ratio indicated: Vitamin C (as 
ascorbic acid and as Mg, Ca, and palmitate ascorbate) 
700 mg; L-lysine 1000 mg; L-proline 750 mg; L-argin-
ine 500 mg; N-acetyl cysteine 200 mg; standardized 
green tea extract (derived from green tea leaves, 
was obtained from US Pharma Lab; the certificate of 
analysis indicated the following characteristics: total 
polyphenol 80%, catechins 60%, epigallocatechin 
gallate (EGCG) 35%, and caffeine 1.0%); 1000 mg; 
selenium 30 μg; copper 2 mg; manganese 1 mg.
MTT assay. Cell viability was evaluated by MTT 
assay, a colorimetric assay based on the ability of 
viable cells to reduce a soluble yellow tetrazolium 
salt [3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetra-
zolium bromide] (MTT) to a blue formazan crystal by 
mitochondrial succinate dehydrogenase activity of 
viable cells. This test is a good index of mitochondrial 
activity and thus of cell viability. After 24 h incubation, 
the cells were washed with phosphate buffered saline 
(PBS) and 500 μl of MTT (Sigma, USA) 0.5 mg/ml in 
media was added to each well. After MTT addition 
(0.5 mg/ml) the plates were covered and returned to 
the 37 °C incubator for 2 h, the optimal time for for-
mazan product formation. Following incubation, the 
supernatant was carefully removed from the wells, 
the formazan product was dissolved in 1 ml DMSO, 
and absorbance was measured at 570 nm in Bio Spec 
1601, Shimadzu spectrometer. The OD570 of the DMSO 
solution in each well was considered to be proportional 
to the number of cells. The OD570 of the control (treat-
ment without supplement) was considered 100%.
Gelatinase zymography. Gelatinase zymography 
was performed in 10% Novex Pre-Cast SDS Polyacryl-
amide Gel (Invitrogen Corporation) in the presence of 
0.1% gelatin under non-reducing conditions. Culture 
media (20 μL) were mixed with sample buffer and 
loaded for SDS-PAGE with Tris glycine SDS buffer, 
as suggested by the manufacturer (Novex). Samples 
were not boiled before electrophoresis. Following 
electrophoresis the gels were washed twice in 2.5% 
Triton X-100 for 30 min at room temperature to remove 
SDS. The gels were then incubated at 37 °C overnight in 
substrate buffer containing 50 mM Tris-HCl and 10 mM 
CaCl2 at pH 8.0 and stained with 0.5% Coomassie Blue 
R250 in 50% methanol and 10% glacial acetic acid 
for 30 min and destained. Upon renaturation of the 
enzyme, the gelatinases digested the gelatin in the 
gel, producing clear bands against an intensely stained 
background. Protein standards were run concurrently 
and approximate molecular weights were determined 
by plotting the relative mobilities of known proteins.
Matrigel invasion. Invasion studies were con-
ducted using Matrigel (Becton Dickinson) inserts in 
24-well plates. Suspended in medium, EOMA cells 
were supplemented with nutrients, as specified in the 
design of the experiment and seeded on the insert in 
the well. Thus both the medium on the insert and in the 
well contained the same supplements. The plates with 
the inserts were then incubated in a culture incubator 
equilibrated with 95% air and 5% CO2 for 24 h. After 
incubation, the media from the wells were withdrawn. 
The cells on the upper surface of the inserts were 
gently scrubbed away with cotton swabs. The cells that 
had penetrated the Matrigel membrane and migrated 
onto the lower surface of the Matrigel were stained with 
hematoxylin and eosin and visually counted under the 
microscope.
Apoptosis. At near confluence, EOMA cells were 
challenged with NM dissolved in media at 0, 100, 500, 
and 1000 μg/ml and incubated for 24 h. The cell culture 
was washed with PBS and treated with the caspase 
reagent as specified in the manufacturer’s protocol 
(Molecular Probes Image-IT™ Live Green Poly Cas-
pases Detection Kit 135104, Invitrogen). The cells were 
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photographed under a fluorescence microscope and 
counted. Green-colored cells represent viable cells, 
while yellow orange represents early apoptosis and 
red, late apoptosis.
Statistical analysis. The results were expressed as 
means + SD, as indicated in the results, for the groups. 
Data was analyzed by independent sample «t» test. 
Pearson’s correlation coefficients were determined for 
toxicity and invasion correlations to NM concentration 
using MedCalc Software (Markakerke, Belgium).
RESULTS
In vivo
Tumor growth. NM strongly inhibited the growth 
of EOMA xenografts in nude mice. Mean tumor weight 
was significantly inhibited (by 50%, p = 0.0001) with NM 
0.5% dietary supplementation, as shown in Fig. 1.
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Fig. 1. Effect of NM on growth of EOMA xenografts in male nude 
mice. NM inhibited the growth of tumors by 50% (p = 0.0001). 
*Indicates significance of p = 0.0001 with respect to control.
Histology. Histologically, the tumors from both 
groups were round, highly vascular invasive tumors 
consistent with cavernous hemangioma with thrombo-
sis. Specimens consisted of two sections from similar 
morphologically round highly vascular invasive tumors 
composed of large, blood-filled cavitary spaces, lined 
by highly anaplastic endothelial cells, which in many 
locations were multilayered. Mitotic figures were infre-
quent. Fibrin thrombi and associated mild neutrophilic 
infiltration were common in the cavernous spaces. 
Tissue from control group showed more extensive 
thrombosis with associated necrosis and inflamma-
tory cell infiltration than did the supplemented group 
specimen (Fig. 2, a–d).
In vitro
Cytotoxicity. NM exhibited dose response toxicity 
on EOMA cells in vitro, with maximum toxicity of 57% 
(p < 0.0001) over the control at 1000 μg/ml, as shown 
in Fig. 3. There was significant negative correlation 
between NM concentration and cell viability, with coef-
ficient r = –0.8323 (p < 0.0001).
Gelatinase zymography. Zymography showed no 
MMP-2 or MMP-9 secretion by normal or PMA-treated 
EOMA cells (not shown).
Matrigel invasion. NM significantly inhibited EOMA 
invasion through Matrigel in a dose-dependent manner, 
with 28% (p = 0.0006) inhibition at 100 μg/ml and 100% 
(p < 0.0001) at 500 μg/ml, as shown in Fig. 4 and 5. 
There was significant negative correlation between NM 
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Fig. 2. Histopathology of tumors. Histologically, tumor specimens 
from both groups were consistent with cavernous hemagioma with 
thrombosis. Specimens consisted of two sections from similar 
morphologically round highly vascular invasive tumors composed 
of large, blood-filled cavitary spaces, lined by highly anaplastic 
endothelial cells, which in many locations were multilayered. Mi-
totic figures were infrequent. Fibrin thrombi and associated mild 
neutrophilic infiltration were common in the cavernous spaces. 
Tissue from control group showed more extensive thrombosis with 
associated necrosis and inflammatory cell infiltration than did the 
supplemented group specimen. a, control 40x; b, control 200x; 
c, NM-supplemented 40x; d, NM-supplemented 200x
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concentration and number of EOMA cells that invaded/
migrated through Matrigel: r = –0.8984, p < 0.0001.
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Fig. 3. Effect of NM on viability of EOMA cells. NM exhibited dose 
response toxicity on EOMA cells in vitro, with maximum toxicity 
of 57% (p < 0.001) over the control at 1000 μg/ml. There was 
significant negative correlation between NM concentration and 
cell viability, with coefficient r = –0.8323 (p < 0.0001). *Indicates 
significance of at least p = 0.002 with respect to control.
0
20
40
60
80
100
120
Control NM 50 μg/ml NM 100 μg/ml NM 500 μg/ml 
Treatment
In
hi
bi
tio
n 
of
 In
va
si
on
, %
 o
f C
on
tro
l
*
*
*
Fig. 4. Effect of NM on Matrigel invasion of EOMA cells. NM 
significantly inhibited EOMA invasion through Matrigel in a 
dose-dependent manner, with 28% (p = 0.0006) inhibition at 
100 μg/ml and 100% (p < 0.00001) at 500 μg/ml. There was 
significant negative correlation between NM concentration and 
number of EOMA cells that invaded/migrated through Matrigel: 
r = –0.8984, p < 0.0001. *Indicates significance of at least p = 
0.05 with respect to control.
Apoptosis. Using the live green caspase kit, dose-
dependent apoptosis of EOMA cells was evident with 
NM challenge, as shown in Fig. 6, a–d. Approximately 
50% of cells exposed to 100 μg/ml NM were apoptotic; 
the number of apoptotic cells increased significantly 
with increased NM concentration. Quantitative analysis 
of live, early and late apoptotic cells is shown in Fig. 7. 
At 100 μg/ml NM, 49% of cells were viable, 16% in early 
apoptosis and 35% in late apoptosis and at 500 μg/ml 
NM 2% of cells were viable, 9% in early apoptosis, and 
89% in late apoptosis. Virtually all cells exposed to 
1000 μg/ml NM were in late apoptosis: 1% viable, 7% 
in early apoptosis and 92% in late apoptosis.
DISCUSSION
Using the EOMA mouse model, dietary supplemen-
tation with 0.5% NM resulted in a dramatic reduction 
(57%) in tumor growth in immune impaired (athymic) 
male nude mice after subcutaneous administration of 
3 x106 EOMA cells. Results from the cellular prolifera-
tion and apoptosis studies support the in vivo findings, 
as NM showed dose-dependent toxicity in EOMA cells 
and induced apoptosis in a dose-dependent manner, 
with 55% inhibition of cell growth and apoptotic induc-
tion of virtually all cells exposed to 500 μg/ml NM. 
Thus, mechanisms of NM-induced inhibition of mouse 
EOMA growth involved both inhibition of proliferation 
and increased tumor cell apoptosis, as seen in the 
natural involution of the more common vascular tumor 
hemangiomas of infancy [15].
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Fig. 5. Effect of NM on Matrigel invasion: photomicrographs. 
a, control; b, NM 50 μg/ml; c, NM 100 μg/ml; d, NM 500 μg/ml
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Invasion of EOMA through Matrigel was also found 
to be significantly inhibited by NM in vitro. As mentioned 
previously, the proliferating phase of hemangioma is 
associated with high expression of type IV collagenases 
and vascular endothelial growth factor (VEGF) [6]. 
Degradation of the ECM by migrating endothelial cells 
and their subsequent invasion of the underlying stroma 
of neighboring tissues where they organize into new 
capillary structures are critical in angiogenesis. Regula-
tion of angiogenesis is achieved through a balance of 
pro- and anti-angiogenic stimuli. The two major pro-
angiogenic factors are MMPs that degrade the ECM and 
vascular endothelial growth factor, a stimulatory factor 
for cell migration. In our previous study on HUVEC, NM 
demonstrated a dose-dependent inhibition of capillary 
tube formation on Matrigel, with completed disruption 
of tubules at 500 μg/ml [13]. Capillary tube formation 
in the basement membrane like matrix of Matrigel is 
a complex process requiring cell-matrix interactions, 
intercellular communications and cell motility.
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Fig. 7. Quantitative analysis of live, early and late apoptotic cells. At 
100 μg/ml NM, 49% of cells were viable, 16% in early apoptosis and 
35% in late apoptosis and at 500 μg/ml NM 2% of cells were viable, 
9% in early apoptosis, and 89% in late apoptosis. At 1000 μg/ml NM: 
1% viable, 7% in early apoptosis and 92% in late apoptosis
The NM was formulated by selecting nutrients that 
act on critical physiological targets in cancer progres-
sion and metastasis. Adequate supplies of ascorbic acid 
and the amino acids lysine and proline, are essential for 
optimal ECM formation and structure as these nutrients 
insure proper synthesis and hydroxylation of collagen 
fibers. Manganese and copper are also essential for 
collagen formation. Lysine also contributes to ECM 
stability as a natural inhibitor of plasmin-induced pro-
teolysis [16, 17]. Green tea extract has been shown to 
control cancer cell growth, metastasis, angiogenesis, 
and other aspects of cancer progression [18–24]. 
N-acetyl cysteine and selenium have been observed 
to inhibit MMP-9 and invasive activities of tumor cells, 
as well as migration of endothelial cells through ECM 
[25–29]. Ascorbic acid has been shown to inhibit tumor 
growth via antiangiogenic activity [30] and to inhibit cell 
division and growth in vitro through production of hydro-
gen peroxide [31]. Arginine is a precursor of nitric oxide 
(NO); any deficiency of arginine can limit the production 
of NO, which has been shown to predominantly act as an 
inducer of apoptosis, as in breast cancer cells [32].
CONCLUSIONS
Current therapy for hemangiomas, such as cor-
ticosteroids, interferon-α and vincristine, all require 
systemic administration and are associated with toxic 
side effects. Thus, they are only used in severe cases 
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Fig. 6. Effect of NM on apoptosis of EOMA cells: live-green cas-
pases. Using the live green caspase kit, dose-dependent apopto-
sis of EOMA cells was evident with NM challenge. Approximately 
50% of cells exposed to 100 μg/ml NM were apoptotic; virtually all 
cells exposed to 500 μg/ml NM were in late apoptosis. a, control; 
b, NM 100 μg/ml; c, NM 500 μg/ml; d, NM 1000 μg/ml
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of hemangiomas and most cases are left untreated. 
The results of the present study show that supple-
mentation with NM was effective in inhibiting growth of 
EOMA xenografts in nude mice and in inhibiting growth 
and Matrigel invasion, as well as inducing apoptosis in 
EOMA cell culture. Furthermore, in contrast to the toxic 
side effects of current treatments, the  NM has been 
shown to be a safe therapeutic agent. In a previous 
in vivo study addressing safety issues, we found that 
gavaging adult female ODS rats (weighing 250–300 g) 
with the  NM (at 30, 90 or 150 mg per day for 7 days), 
had neither adverse effects on vital organs (heart, liver 
and kidney), nor on the associated functional serum 
enzymes, indicating that this mixture is safe to use 
even at these high doses, which far exceed the normal 
equivalent dosage of the nutrient [33]. While clinical 
studies are necessary to better determine the efficacy 
of nutrient therapy in hemangiomas, the results of this 
study suggest the NM may have therapeutic potential 
in treating infantile hemangioendotheliomas and other 
cutaneous vascular tumors with minimal toxic effect.
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